ATC Group: C10AA HMG CoA reductase inhibitors

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C10AA in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C10 Lipid modifying agents
3 C10A Lipid modifying agents, plain
4 C10AA HMG CoA reductase inhibitors

Group C10AA contents

Code Title
C10AA01 Simvastatin
C10AA02 Lovastatin
C10AA03 Pravastatin
C10AA04 Fluvastatin
C10AA05 Atorvastatin
C10AA06 Cerivastatin
C10AA07 Rosuvastatin
C10AA08 Pitavastatin

Active ingredients in C10AA

Active Ingredient

Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.

Fluvastatin, a fully synthetic cholesterol-lowering agent, is a competitive inhibitor of HMG-CoA reductase, which is responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Fluvastatin reduces total-C, LDL-C, Apo B, and triglycerides, and increases HDL-C in patients with hypercholesterolaemia and mixed dyslipidaemia.

Lovastatin, which is an inactive lactone, is hydrolysed after oral administration to the corresponding β-hydroxyacid. This is the major metabolite and an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, an enzyme that catalyses an early and rate-limiting step in the biosynthesis of cholesterol.

Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the biosynthesis of cholesterol, and inhibits cholesterol synthesis in the liver.

Pravastatin is a competitive inhibitor of 3-hydroxy–3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme catalyzing the early rate limiting step in cholesterol biosynthesis, and produces its lipid lowering effect in two ways.

Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase. Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.

Simvastatin has a potent activity in inhibiting HMG-CoA reductase (3-hydroxy–3-ethylglutaryl-CoA-reductase). Simvastatin has been shown to reduce both normal and elevated LDL-C concentrations.

Related product monographs

Document Type Information Source  
 ASPAVOR Film-coated tablet MPI, Generic Web Search
 ATORSTAN Film-coated tablet MPI, EU: SmPC Υπουργείο Υγείας (CY)
 CRESTOR Film-coated tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 DEZZOLIP Film-coated tablet MPI, Generic Health Products Regulatory Authority (ZA)
 LESCOL XL Extended-release tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 LESTAVOR Film-coated tablet MPI, Generic Marketing Authorisation Holder
 LIPITOR Film-coated tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 LIPITOR Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 LIVALO Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 LIVAZO Film-coated tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 PRAVACHOL Tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 SIMCARD Film-coated tablet MPI, Generic Health Products Regulatory Authority (ZA)
 STATOL Film-coated tablet MPI, EU: SmPC Υπουργείο Υγείας (CY)
 ZOCOR Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 ZUVAMOR Film-coated tablet MPI, Generic Health Products Regulatory Authority (ZA)